` Comparison: ONCO, PNEXF - Alpha Spread

ONCO
vs
PNEXF

Over the past 12 months, ONCO has significantly outperformed PNEXF, delivering a return of +103% compared to the PNEXF's 0% growth.

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
ONCO
PNEXF
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Valuation
Growth
Profitability
Solvency
Comparing Valuation
Running a multi-layered valuation analysis to compare how attractive each stock is.
Comparing Growth
Financial growth, forecasts, volatility, and historical drawdowns.
Comparing Profitability
Margins, returns on capital, and the consistency of profitability.
Comparing Solvency
Debt levels, liquidity, interest coverage, and bankruptcy risk.
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

ONCO Intrinsic Value
3.1 SEK
Overvaluation 32%
Intrinsic Value
Price
PNEXF Intrinsic Value
Not Available
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
Oncopeptides AB
STO:ONCO
4.53 SEK
Pharnext SCA
OTC:PNEXF
999 999.9999 USD
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
ONCO, PNEXF

ONCO
PNEXF
Add Stock
Revenue
www.alphaspread.com
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
Oncopeptides AB
Revenue
Pharnext SCA
Revenue

All metrics are calculated based on data from the last 10 years.

Profitability Comparison

Free Cash Flow
ONCO, PNEXF

ONCO
PNEXF
Add Stock
Free Cash Flow
www.alphaspread.com
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
Oncopeptides AB
STO:ONCO
Pharnext SCA
OTC:PNEXF
What is Free Cash Flow?

Gross Margin

ONCO
94.3%
PNEXF
0%
LTM 3Y Avg 5Y Avg 10Y Avg
Oncopeptides AB
Pharnext SCA

Operating Margin

ONCO
-696.9%
PNEXF
-17 526.7%
LTM 3Y Avg 5Y Avg 10Y Avg
Oncopeptides AB
Pharnext SCA

Net Margin

ONCO
-696.7%
PNEXF
-21 040%
LTM 3Y Avg 5Y Avg 10Y Avg
Oncopeptides AB
Pharnext SCA

FCF Margin

ONCO
-656.4%
PNEXF
-15 953.3%
LTM 3Y Avg 5Y Avg 10Y Avg
Oncopeptides AB
Pharnext SCA

ROE

ONCO
3 890%
PNEXF
114.6%
LTM 3Y Avg 5Y Avg 10Y Avg
Oncopeptides AB
Pharnext SCA

ROA

ONCO
-148.8%
PNEXF
-391.1%
LTM 3Y Avg 5Y Avg 10Y Avg
Oncopeptides AB
Pharnext SCA

ROIC

ONCO
-416.9%
PNEXF
3 092.9%
LTM 3Y Avg 5Y Avg 10Y Avg
Oncopeptides AB
Pharnext SCA

ROCE

ONCO
-215.1%
PNEXF
275.4%
LTM 3Y Avg 5Y Avg 10Y Avg
Oncopeptides AB
Pharnext SCA

Solvency Comparison

Balance Sheet Comparison

Stocks Performance

Stocks Performance
ONCO, PNEXF

Loading

Performance Gap
ONCO, PNEXF

Loading
ONCO
PNEXF
Difference
www.alphaspread.com

Performance By Year
ONCO, PNEXF

Loading
ONCO
PNEXF
Add Stock
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare ONCO to other stocks
Unlock Full Access to Alpha Spread
Create Free Account